Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Broccoli, Alessandro"'
Autor:
Alessandro Pulsoni, Barbara Botto, Alessandro Re, Manuel Gotti, Michele Spina, Luigi Rigacci, Andrea Evangelista, Sofia Kovalchuk, Daniela Gioia, Lara Mannelli, Manjola Dona, Luca Nassi, Benedetta Puccini, Alessandro Broccoli, Caterina Stelitano, Flavia Salvi, Armando Santoro, Chiara Pagani, Pier Luigi Zinzani, Maurizio Bonfichi
FDG-positron emission tomography (PET) performed early during therapy in advanced Hodgkin lymphoma patients has been confirmed as being important for progression-free survival. A group of patients with a negative interim-PET (i-PET) showed a positive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05cb996a2f3f72571286dbb535a49edb
http://hdl.handle.net/11573/1347613
http://hdl.handle.net/11573/1347613
Autor:
Nicola Cascavilla, Cristina Tecchio, Carlo Visco, Annalisa Chiappella, Maria Christina Cox, Roberto Marasca, Rossella Paolini, Beatrice Casadei, Gerardo Musuraca, Caterina Patti, Michelle Zancanella, Annarita Conconi, Maria Goldaniga, Angelo Fama, Dario Marino, Francesco Gaudio, Claudia Castellino, Alessandra Romano, Luigi Rigacci, Monica Tani, Monica Balzarotti, Federico Monaco, Alessandro Broccoli, Lisa Argnani, Liliana Devizzi, Pier Luigi Zinzani
Background Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma subtype, and approximately 50% of the patients are >60 years of age. Patients with relapsed/refractory (rr) disease have a poor prognosis with currently availabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98a63b4ae6076e247de8356a0953673f
https://europepmc.org/articles/PMC6738312/
https://europepmc.org/articles/PMC6738312/
Autor:
Maurizio Boaron, Luca Bertolaccini, Barbara Bonfanti, Sergio Nicola Forti Parri, Alessandro Broccoli, Claudio Agostinelli, Stefano Fanti, Lisa Argnani, Beatrice Casadei, Cinzia Pellegrini, Pier Luigi Zinzani, Cristina Nanni
Publikováno v:
Leukemialymphoma. 60(9)
Residual masses in patients with mediastinal lymphoma may be positron emission tomography (PET) positive during follow-up also in cases of complete response. The aim of this retrospective study is to verify the reliability of mediastinal PET-positive
Autor:
Vittorio Stefoni, Vincenzo Pavone, Lisa Argnani, Alessandra Romano, Michele Merli, Pier Luigi Zinzani, Amalia De Renzo, Pellegrino Musto, Gian Matteo Rigolin, Maria Goldaniga, Luigi Rigacci, Monica Tani, Donato Mannina, Michele Spina, Angelo Michele Carella, Anna Marina Liberati, Armando Santoro, Alessandro Pulsoni, Patrizio Mazza, Corrado Schiavotto, Livio Trentin, Chiara Rusconi, Anna Vanazzi, Caterina Patti, Stefan Hoaus, Stefano Molica, Stefano Volpetti, Guido Gini, Maurizio Bonfichi, Maria Paola Bianchi, Paolo Corradini, Antonello Pinto, Alessandro Broccoli, Patrizia Tosi, Fioravante Ronconi, Filippo Gherlinzoni, Barbara Botto, Giuseppe Gritti, Daniele Vallisa, Cinzia Pellegrini, Francesco Gaudio, Angelo Fama
Publikováno v:
Oncotarget
A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94457167f00c920b149713c4f8512072
http://hdl.handle.net/11585/615058
http://hdl.handle.net/11585/615058
Publikováno v:
Biologics : Targets & Therapy
Valentina Perrone,1 Stefania Saragoni,1 Stefano Buda,1 Alessandro Broccoli,2 Luca Degli Esposti1 1CliCon S.r.l., Health, Economics & Outcomes Research, Ravenna, 2Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy
Autor:
Caterina Stelitano, Waldemar Kulikowski, Alessandra Romano, Lisa Argnani, Luigi Rigacci, Alessandro Levis, Fabio Fuligni, Pier Paolo Piccaluga, Anna Borra, Randy D. Gascoyne, Francesco d'Amore, Bogdan Małkowski, Claudio Agostinelli, Edyta Subocz, Stefano Pileri, Pier Luigi Zinzani, Livio Trentin, Luisa Stracqualursi, Maria Teresa Sista, Stephen Hamilton-Dutoit, Caterina Patti, Claudio Tripodo, Andrea Gallamini, Jan Maciej Zaucha, Alessandro Broccoli, Stefano Fanti, Francesco Merli, Alberto Biggi, Christian Steidl, Justyna Rybka, Umberto Vitolo, Joanna Tajer, Patrizia Agati, Peter Kamper
Publikováno v:
Agostinelli, C, Gallamini, A, Stracqualursi, L, Agati, P, Tripodo, C, Fuligni, F, Sista, M T, Fanti, S, Biggi, A, Vitolo, U, Rigacci, L, Merli, F, Patti, C, Romano, A, Levis, A, Trentin, L, Stelitano, C, Borra, A, Piccaluga, P P, Hamilton-Dutoit, S, Kamper, P, Zaucha, J M, Małkowski, B, Kulikowski, W, Tajer, J, Subocz, E, Rybka, J, Steidl, C, Broccoli, A, Argnani, L, Gascoyne, R D, d'Amore, F, Zinzani, P L & Pileri, S A 2016, ' The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma : a retrospective, European, multicentre cohort study ', The Lancet. Haematology, vol. 3, no. 10, pp. e467-e479 . https://doi.org/10.1016/S2352-3026(16)30108-9
BACKGROUND: Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e938ba130f6b8eebdc3e9dca76c61cbe
https://hdl.handle.net/20.500.11769/542314
https://hdl.handle.net/20.500.11769/542314